Practice Areas: New Product Planning, Business Development and Licensing, Commercial Strategy and Analytics, and Epidemiology and Forecasting. Our boutique expertise is focused on elucidating patient benefits of bio-pharmaceutical products, medical devices, and businesses. With insightful strategies and solutions aimed at planning and growing our clients’ business, our mission is to continue being the “go-to” firm and preferred partner for our clients in their commercial planning and R&D initiatives. Our chief operating principle is an unsurpassable commitment to quality and our philosophy has been to develop and sustain strong long-term relationships with clients based on an in-depth understanding of client needs, rigorous research, sound methodologies, and keeping ahead of industry developments.

1. © 2016 Gore & Company
All rights reserved. This information is proprietary, confidential, and not reproducible.
Page 1
A Boutique Consulting Firm
Practice Areas and Capabilities
Therapeutic Areas
Neuroscience
Anti-Infectives
Dermatology
Cardiovascular
Oncology
Immunology
Rare Disease
Gene Therapy
77 Franklin Street | Suite 514
Boston | Massachusetts
Metabolic

2. © 2016 Gore & Company
All rights reserved. This information is proprietary, confidential, and not reproducible.
Page 2
A Boutique Pharmaceutical Strategy Consulting Firm
Few Select Clients With Long-Term Relationships
We have developed our consulting practice since year 2000 based on key founding principles:
 The firm’s chief operating principle since its inception has been an unsurpassable
commitment to quality and our philosophy has been to develop and sustain strong long-term
relationships with clients based on an in-depth understanding of client needs, rigorous
research, sound methodologies, and keeping ahead of industry developments.
 Our boutique expertise is focused on elucidating patient benefits of bio-pharmaceutical
products, medical devices, and businesses. With insightful strategies and solutions aimed at
planning and growing our clients’ business, our mission is to continue being the “go-to” firm
and preferred partner for our clients in their commercial and R&D initiatives.
 Based on this foundation of experience, expertise and a reputation for quality, our vision for
the future is to solidify our position as a unique strategy consulting firm that stays true to our
core principles of integrity, scientific rigor, conducting research of unsurpassable quality, and
adding value to our client’s business in every step of the way.
Who we are?
We are well-positioned to serve our Client Teams on diverse engagements
Therapeutic Areas
Neuroscience
Anti-Infectives
Dermatology
Cardiovascular
Oncology
Immunology
Rare Disease
Gene Therapy
Metabolic

3. © 2016 Gore & Company
All rights reserved. This information is proprietary, confidential, and not reproducible.
Page 3
Strategic and Insightful Thinking
Based on Rigorous and Innovative Processes and Methods
Solutions and strategies for client assets and businesses based on considerable experience
in neuroscience, oncology, cardiovascular disease, dermatology, metabolic disorders,
immunology and inflammation, and orphan diseases.
Partnering with CLIENT teams to provide strategic business development and licensing
expertise in major therapeutic areas as well as orphan indications.
More than a decade’s experience working on major (United States, EU, and Japan) and
emerging markets (China, India, and Asia-Pacific) with added capabilities of working on
China and India specific projects.
Strong understanding of CLIENT priorities and processes.
Our best value offering is thinking strategically through a problem, generating alternatives,
and identifying the best solutions.
What we offer?
We focus on helping clients with what they don’t know as opposed to summarizing what they already know!
Therapeutic Areas
Neuroscience
Anti-Infectives
Dermatology
Cardiovascular
Oncology
Immunology
Rare Disease
Gene Therapy
Metabolic

4. © 2016 Gore & Company
All rights reserved. This information is proprietary, confidential, and not reproducible.
Page 4
Global Pharmaceutical Strategy Consultants
Practice Areas and Capabilities
Our experience and background promotes us as the consulting firm of choice for the Business
Development and Licensing needs of the global bio-pharmaceutical industry.
We focus on 4 core offerings in our consulting practice:
 Market Planning
 Business Development and Opportunity Assessment
Market and Therapeutic Area Assessment
Product Assessment
Technology Assessment
Licensing Evaluations
 New Product Planning
 Forecasting and Portfolio Valuation
What we do?
Therapeutic Areas
Neuroscience
Anti-Infectives
Dermatology
Cardiovascular
Oncology
Immunology
Rare Disease
Gene Therapy
Metabolic

5. © 2016 Gore & Company
All rights reserved. This information is proprietary, confidential, and not reproducible.
Page 5
Neuroscience
Cardiovascular
Immunology
Oncology
Ophthalmology
Dermatology
Anti-Infectives
Rare Disease
KEY: Work Done in Past For: Mid-Size Pharma BiotechBig Pharma
Market Planning
New Product
Planning
Forecasting and
Valuation
Opportunity
Assessment
Therapeutic Area Experiences
Select Engagements Since Year 2000

6. © 2016 Gore & Company
All rights reserved. This information is proprietary, confidential, and not reproducible.
Page 6
Business Development
Strategy and Process
Franchise Strategy
New Product Planning
Valuation and Decision-
Making
Areas Where We Assist Our Clients
Corporate Goal
Opportunity Assessment
Revenue and Growth Expectations
Which therapeutic areas should we
pursue? And which diseases?
How do we prioritize our R&D portfolio
and how do we fill the portfolio gaps?
Which opportunities should we pursue
and why?
What should we know before we invest
in a drug candidate? – TPP / APC
What is the opportunity valuation and
the logic behind our go/no go decision?

7. © 2016 Gore & Company
All rights reserved. This information is proprietary, confidential, and not reproducible.
Page 7
Our strategic methods enable our clients to answer key questions
surrounding potential business opportunities
Key Questions Answered
 What are the potential business opportunities within our key business areas that will grow our
revenue and earnings?
 What is the optimal target profile for a new drug to be successful in the future competitive
environment?
 What are the key issues pertaining to our target indications, patient populations, and competitive
markets?
 What will be the impact of novel technologies and platforms on our R&D programs and long-term
business competitiveness?
 What is the forecasted potential and risk of our portfolio based on technical, clinical, and
commercial feasibility perspectives?
New Product
Planning
Forecasting and
Portfolio Valuation
Opportunity
AssessmentMarket Planning

8. © 2016 Gore & Company
All rights reserved. This information is proprietary, confidential, and not reproducible.
Page 8
Our market planning tools and processes are geared to optimize our
clients’ business portfolios
Market Planning
 Develop futuristic healthcare scenarios as a framework for business planning
 Identify and evaluate potential business opportunities within key growth areas
 Create business cases for management to facilitate resource allocation decisions
Key Objectives
Corporate Mission
and Goals


Competitive Strategy
Corporate Strategy


Acquisitions
Alliances
Licensing
Business
Development
Assessment
Valuation
BUSINESS
PORTFOLIO
Optimization
Opportunity
Realization
Business
Requirements
Opportunity
Assessment
Business
Plans
Opportunity
Realization
ExternalInternal




 


9. © 2016 Gore & Company
All rights reserved. This information is proprietary, confidential, and not reproducible.
Page 9
Using our research, clinical, and market expertise, we have devised
unique tools to conduct BD, licensing, and opportunity assessments
Opportunity
Assessment




 

Business
Requirements
Business
Plans
Gap Analysis
Opportunity
Screening
Opportunity
Identification
Market
Assessment
Product
Assessment
Technology
Assessment
1
2
3
TOOL KIT
Opportunity
Selection
Opportunity
Realization
Opportunity
Valuation
Assessment
Processes
• Corporate Processes
• Business Development
• Licensing Processes
• Internal Reviews
Assessment
Tools
• Indication Attractiveness
• Market Attractiveness
• Product Attractiveness
• Target Profile Symmetry
Valuation
Tools
• Strategic Fit Evaluation
• Discounted Cash Flow
• Decision Tree Analysis
• Option Valuation Model
InternalExternal
Opportunity Set
Opportunity
Assessment
BUSINESS
PORTFOLIO
 Assess current and future unmet medical needs in the market
 Determine target profiles of technologies and drugs needed to replace standards of care
 Analyze and select opportunities that maximize the value of the business portfolio
Key Objectives

10. © 2016 Gore & Company
All rights reserved. This information is proprietary, confidential, and not reproducible.
Page 10
Market Assessment
 Identify and define markets by geography, patient segments, and provider structures
 Assess the impact of market trends and dynamics on products and business
 Identify and prioritize market opportunities for product growth
Key Objectives
Our in-depth analysis and evaluation enables our clients to assess the
impacts of market trends and dynamics on their products
Grab Market
Opportunities
Opportunity
Prioritization
Marketing
Solutions
Opportunity
Evaluation
Define Market Patient
Characteristics
Competitor
Characteristics
Disease
Characteristics
Market
Characteristics
Analyze Market Competitive
Dynamics
Payor and
Provider
Market Size
and Growth
Emerging
Trends
Identify Market
Opportunities
Provider
Needs
Patient
Segments
Unmet Medical
Needs
Payor Needs
Business
Planning
KEY MARKET ASSESSMENT COMPONENTS

11. © 2016 Gore & Company
All rights reserved. This information is proprietary, confidential, and not reproducible.
Page 11
Product Assessment
 Evaluate critical technical, clinical, and market attributes of products
 Identify key advantages and disadvantages over competitors
 Assess critical product differentiators to optimally position product
Key Objectives
Our methods of conducting product assessments enable our clients to
better position their products in the market
CRITICAL PRODUCT ATTRIBUTES
1
2
3
Technical
• Active Molecule
• Mechanism of Action
• Formulation Characteristics
• ADME Profile
Clinical
• Efficacy
• Safety
• Dosage Form
• Frequency of Dosing
Market
• Patient, Provider, and Payor
• Price
• Formulary Characteristics
• Reimbursement
COMPETITIVECOMPARISONS
CLIENT
COMPETITOR
Product
Assessment
Weaknesses
Strengths
Differentiators
Positioning
Strategy
Tactics
Market
Influences
Opportunities
and Threats

12. © 2016 Gore & Company
All rights reserved. This information is proprietary, confidential, and not reproducible.
Page 12
Technology
Assessment
Develop Technology
Based Strategy
Identify
Technologies
Bioinformatics
Cardiovascular
Angiogenesis
Growth Factors
Anticoagulation
Factors
CardioScans
Oncology
Cancer
Vaccines
Biomarkers
Herceptin
Genomics
CNS
Stem Cell
Therapy
Nerve Growth
Factor
APOE
Genotyping
ProteomicsEnabling
Diagnostic
Prophylactic
Therapeutic
APPLICATION
KEY CLIENT THERAPEUTIC AREAS
Understand Key
Technology Impacts
Profile and Analyze
Technologies
 Synergistic
 Competitive
 Disruptive
 Synthesize
 Align
 Evaluate
Scan Technology
Market
 Evaluate the technical and commercial feasibility of innovative technologies
 Assess the impact of novel technologies on R&D programs and long-term business
 Incorporate new technologies and research tools to re-engineer R&D processes
Key Objectives
Our in-depth analysis and evaluation enables our clients to assess the
critical impacts of new technologies on their business

13. © 2016 Gore & Company
All rights reserved. This information is proprietary, confidential, and not reproducible.
Page 13
Our systematic approach to new product planning enables our clients to
strategically plan for their new products
Phase III
Phase II
Phase I
Preclinical
PRODUCT STAGE
• Analyze drivers and
trends for indications
• Explore disease
pathogenesis
• Determine unmet
medical needs
• Identify target indications
and explore target patient
subsets
• Develop indication
strategies
• Initiate life-cycle
management based on
potential indications
• Evaluate competitive
pipelines
• Assess level of
innovations in pipeline
• Determine level of threat
from emerging
competitors
• Conduct SWOT analysis
on current competitors
• Identify key gaps not met
by competitors
• Assess market needs to
be competitive
• Determine potential
positioning to compete in
target markets
• Explore gaps in medical
and market needs
• Profile drug candidate
versus current and future
standard of care
• Determine what it will
take to achieve target
profile
• Create target profile for
successful market entry
• Formulate development
strategy for indications
based on drug
candidate’s target profile
• Design clinical trials and
their outcomes to
demonstrate target
profile
Market ForecastsTarget Profile
Competitive
Landscape
Indication Profile
• Identify likely competitors
at time of launch
• Determine relative
attractiveness of
potential competitors
• Estimate patient and/or
RX volume at time of
launch
• Develop market models
to estimate revenue
potential
• Identify optimal valuation
method for NPVs
• Estimate NPVs
• Recommend Go/No Go
for drug candidate
New Product
Planning
 Understand emerging market needs and corresponding target profiles for new products
 Conduct in-depth analyses of targeted indications, patient populations, and competition
 Forecast market potential under various market scenarios
Key Objectives

14. © 2016 Gore & Company
All rights reserved. This information is proprietary, confidential, and not reproducible.
Page 14
Forecasting and
Portfolio Valuation
Business
Requirements
Business
Plans
Strategic Fits
Portfolio
Selection
Selected
Portfolio
1
2
3
Potential
Portfolios
Portfolio
Planning
Portfolio
Selection
Valuation Tool
Portfolio
Analysis
Portfolio
Optimization
• Strategic Fit Evaluation
• Optimization Parameters
• Optimization Analysis
• Solution Set
Portfolio
Candidates
Portfolio
Valuation
OPTIMIZED
PORTFOLIO
Corporate Goals
and Strategy
Opportunity
Assessment
• Discounted Cash Flow
• Decision Tree Analysis
• Black-Scholes Option Model
• Investment Needs
• Potential Revenues
• NPV of Portfolio Candidates
• Portfolio Value
 Derive financial forecasts based a technical, clinical, and commercial analysis perspectives
 Analyze and forecast portfolio potential using in-depth modeling processes
 Facilitate management in “Go/No Go” decision-making to optimize the business portfolio
Key Objectives
Our unique valuation tools enable our clients to select, plan, and
optimize their business and R&D portfolios
FINANCIAL FORECASTING TOOLS

15. © 2016 Gore & Company
All rights reserved. This information is proprietary, confidential, and not reproducible.
Page 15
Find Us
Write Us
77 Franklin Street, Suite 514, Boston, MA 02110
Visit Us
www.goreconsulting.com
Therapeutic Areas
Neuroscience
Anti-Infectives
Dermatology
Cardiovascular
Oncology
Immunology
Rare Disease
Gene Therapy
Metabolic